Group 1 - Acadia Pharmaceuticals has a strong history of beating earnings estimates, with an average surprise of 87.50% over the last two quarters [1] - In the most recent quarter, Acadia reported earnings of $0.20 per share, exceeding the expected $0.16 per share by 25%, and in the previous quarter, it reported $0.10 per share against an estimate of $0.04 per share, resulting in a surprise of 150% [1] - Recent estimates for Acadia have been moving higher, with a positive Zacks Earnings ESP indicating a strong potential for another earnings beat [2][3] Group 2 - The Zacks Earnings ESP for Acadia is currently +0.92%, suggesting that analysts have recently become more optimistic about the company's earnings prospects [3] - The combination of a positive Earnings ESP and a Zacks Rank 1 (Strong Buy) indicates a high likelihood of another earnings beat for Acadia [3] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [2]

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Acadia Pharmaceuticals (ACAD) and Techne (TECH) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank emphasizes companies with pos ...

A month has gone by since the last earnings report for Acadia Pharmaceuticals (ACAD) . Shares have added about 10% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Acadia due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Acadia Q2 Earnings Beat, Product Sales Drive ...

Acadia Pharmaceuticals Inc. (ACAD) reported second-quarter 2024 earnings of 20 cents per share, beating the Zacks Consensus Estimate of 16 cents. In the year-ago quarter, the company had recorded earnings of 1 cent per share.The bottom line improved year over year owing to higher product sales.Acadia recorded total revenues of $242 million, which beat the Zacks Consensus Estimate of $235 million. ACAD’s net product revenues comprise revenues generated from the sale of its two marketed products, Nuplazid (pi ...

Financial Data and Key Metrics Changes - ACADIA Pharmaceuticals reported total net sales of $242 million for Q2 2024, representing a 46% year-over-year increase [47] - DAYBUE net product sales reached $84.6 million, up from $23.2 million in Q2 2023, marking an 11% sequential growth [47] - NUPLAZID net product sales were $157.4 million, reflecting an 11% increase compared to the same quarter last year [47] Business Line Data and Key Metrics Changes - DAYBUE experienced a sequential increase in active patients, reaching 900, which is consistent with the end of 2023 [8][9] - NUPLAZID's sales growth was supported by a stabilization in the Parkinson's disease psychosis market and positive real-world evidence studies [10][27] - The company adjusted its guidance for DAYBUE sales down to a range of $340 to $370 million for the year, while increasing NUPLAZID's guidance to $590 to $610 million [50][51] Market Data and Key Metrics Changes - The awareness of hallucinations and delusions among patients and caregivers has significantly decreased, creating an opportunity for ACADIA to raise awareness through targeted campaigns [31][34] - Approximately 30% of diagnosed Rett syndrome patients in the U.S. have initiated DAYBUE treatment, indicating a substantial market opportunity for growth [18][22] Company Strategy and Development Direction - ACADIA is focused on expanding its commercial franchises, particularly DAYBUE and NUPLAZID, while also advancing its pipeline programs, including those for Prader-Willi syndrome and Alzheimer's disease psychosis [7][12] - The company plans to initiate a targeted campaign to address the awareness gap regarding hallucinations and delusions in Parkinson's disease patients [11][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to fund future growth with over $500 million in cash and no debt [8] - The management team acknowledged that while progress is being made, the rate of new patient starts for DAYBUE has been slower than anticipated, leading to a cautious outlook for the second half of the year [9][50] Other Important Information - R&D expenses increased to $76.2 million in Q2 2024, primarily due to costs associated with pipeline programs [48] - SG&A expenses rose to $117.1 million, driven by new consumer activation programs and marketing costs [49] Q&A Session Summary Question: Discontinuation and New Start Rates - The management noted that discontinuation rates are consistent between Centers of Excellence (COEs) and community practices, with a higher penetration of prescriptions expected from community practices over time [56][57] Question: DAYBUE Guidance Confidence - Management indicated that they are tracking towards the lower half of the revised guidance range for DAYBUE, with potential to reach the higher end based on ongoing initiatives [60][62] Question: Impact of Summer Months on DAYBUE - Management acknowledged that summer months typically see some patient cycling, but they expect new patient starts to progress as families return from vacations [65][66] Question: Breakdown of Untreated Patients - Management clarified that the remaining 70% of diagnosed patients not on DAYBUE are primarily in the younger age range, with physicians expecting to increase prescriptions significantly in the coming years [70][72]

Commercial Products - NUPLAZID and DAYBUE are the company's commercial portfolio products, with NUPLAZID approved in April 2016 and DAYBUE in March 2023[87][98]. - The FDA approved DAYBUE for Rett syndrome, with the product launched in the U.S. in April 2023, following positive results from the Phase 3 LAVENDER™ study[89][98]. - The company holds worldwide commercialization rights to NUPLAZID and has a strategy to expand its pipeline through strategic business development[88][86]. Financial Performance - Net product sales for the three months ended June 30, 2024, were $242.0 million, up from $165.2 million in the same period of 2023, representing a 46.5% increase[111]. - Net product sales of NUPLAZID increased to $157.4 million for the three months ended June 30, 2024, compared to $142.0 million in 2023, a growth of $15.4 million[111]. - Net product sales of DAYBUE surged to $84.6 million for the three months ended June 30, 2024, from $23.2 million in 2023, reflecting an increase of $61.4 million[111]. Research and Development - The company has incurred substantial operating losses and expects to continue incurring losses due to significant research and development costs[96]. - Research and development expenses for the first half of 2024 are expected to increase due to advancements in early-stage development pipeline programs[101]. - The company anticipates that research and development expenses will remain substantial as it continues to develop ACP-101, ACP-204, and other early-stage programs[106]. - The company is developing ACP-204 for Alzheimer's disease psychosis, with a Phase 2 study initiated in November 2023[94]. Operating Expenses - Selling, general and administrative expenses increased to $117.1 million for the three months ended June 30, 2024, from $96.0 million in 2023, a rise of 22.0%[116]. - Selling, general and administrative expenses increased to $225.1 million for the six months ended June 30, 2024, up from $197.2 million for the same period in 2023, driven by costs related to a new consumer activation program and increased marketing expenses[123]. - The increase in selling, general and administrative expenses was primarily driven by upfront costs related to the NUPLAZID franchise and investments for commercialization of trofinetide outside the U.S.[123]. Cash Flow and Financing - Cash, cash equivalents, and investment securities totaled $500.9 million at June 30, 2024, an increase of $62.0 million from $438.9 million at December 31, 2023, primarily due to cash provided by operating activities[131]. - Net cash provided by operating activities increased to $54.1 million for the six months ended June 30, 2024, compared to a net cash used of $9.7 million for the same period in 2023[131]. - Future capital requirements may increase significantly due to costs associated with acquiring additional product candidates and the scope of research and development programs[125]. - The company may require additional financing in the future, which could be affected by market conditions and the ability to generate cash from operations[127]. - The company expects its cash, cash equivalents, and investment securities to be sufficient to fund planned operations through and beyond the next 12 months[124]. Licensing and Agreements - The expanded licensing agreement with Neuren in July 2023 included an upfront payment of $100 million and potential milestone payments of up to $1.257 billion[91]. - The company plans to file for pediatric investigation plan approval in Europe in Q1 2025 and has initiated discussions with regulatory agencies in Japan and Canada[92]. - The company plans to make milestone payments of $50.0 million in the next 12 months if aggregate net revenue of trofinetide in North America exceeds $250.0 million[130]. Cost of Sales - The cost of sales for DAYBUE was affected by the use of initial pre-launch inventory, with expectations that costs will stabilize as full-cost inventories are sold[100]. - Cost of product sales for the six months ended June 30, 2024, was $41.2 million, compared to $9.1 million in 2023, representing an increase of 352.7%[119]. - License fees and royalties for DAYBUE increased to $23.7 million for the six months ended June 30, 2024, from $3.7 million in the same period of 2023[119].

○ ACADIA Second Quarter 2024 Earnings Call August 6, 2024 Call Agenda Welcome Al Kildani | Senior Vice President, Investor Relations and Corporate Communications CEO Opening Remarks Steve Davis | President and Chief Executive Officer Commercial Update Brendan Teehan | Chief Operating Officer, Head of Commercial R&D Update Elizabeth Thompson | Executive Vice President, Head of Research and Development Financial Update Mark Schneyer | Chief Financial Officer Closing Remarks Steve Davis | President and Chief E ...

分组1 - Acadia Pharmaceuticals reported quarterly earnings of $0.20 per share, exceeding the Zacks Consensus Estimate of $0.16 per share, and showing a significant increase from $0.01 per share a year ago, representing an earnings surprise of 25% [1] - The company achieved revenues of $241.96 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 2.85%, and up from $165.24 million year-over-year [1] - Over the last four quarters, Acadia has surpassed consensus EPS estimates three times and has also topped consensus revenue estimates three times [1] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.13 on revenues of $251.11 million, while for the current fiscal year, the estimate is $0.58 on revenues of $952.88 million [4] - The Medical - Biomedical and Genetics industry, to which Acadia belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [5] - G1 Therapeutics, another company in the same industry, is expected to report a quarterly loss of $0.17 per share, reflecting a year-over-year change of -221.4%, with revenues anticipated to be $15.88 million, down 62.6% from the previous year [5][6]

Exhibit 99.1 Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview - Second quarter total net product sales of $242.0 million, up 46% year-over-year SAN DIEGO, CA, August 6, 2024 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2024. "In the second quarter of 2024, Acadia delivered $242.0 million in net product sales, highlighted by 11% year-over-year growth in NUPLAZID net sales and 11% sequential ...

The market expects Acadia Pharmaceuticals (ACAD) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to b ...